CD40 ligand (CD40L or CD154) and CD40 receptor-mediated activation of dendritic cells (CD40L-mediated DC activation or CD40-CD40L pathway)

CD40 ligand-mediated dendritic cell activation is a key pathway in the immune system in which binding of the CD40 ligand (CD154/CD40L), typically expressed on activated T cells, to its receptor CD40 on dendritic cells triggers their maturation. This results in upregulation of antigen-presentation machinery (MHC molecules), costimulatory molecules (CD80, CD86), and the production of cytokines such as IL-12, all of which enable DCs to effectively prime T cells, especially cytotoxic CD8^+^ T cells. The pathway is crucial for shaping adaptive immune responses, including those against cancer, infections, and in the development of autoimmunity. Therapeutically, both the receptor and ligand are targets for immune modulation, either to boost immune responses (e.g., in cancer) or suppress them (e.g., in autoimmunity and transplantation). Safety challenges exist due to the potent immunostimulatory effects and risk of cytokine release or vasoactive complications.

Other names

CD40 ligandCD154TRAP (Tumor necrosis factor receptor-associated protein)T-BAMCD40 receptor (target on dendritic cells)CD40 signaling axis

Agonism: Engaging CD40 on DCs to stimulate maturation and cytokine production. Antagonism: Blocking CD40/CD40L interaction to suppress pathological immune activation (autoimmunity, transplant rejection). Adjuvant effect: Augmenting T cell responses in cancer immunotherapy by boosting DC function.